Abstract
Objective
The aim of our study was to assess the value of dynamic contrast-enhanced magnetic resonance imaging (DMRI) in predicting early response to neoadjuvant chemotherapy (NAC) in patients with locally advanced breast cancer (LABC) and to assess the accuracy of DMRI in evaluating residual disease after NAC.
Methods
DMRI were performed in 43 women with LABC (44 lesions, all were invasive ductal carcinoma) before, after the first and final cycle of NAC. Tumour volume, early enhanced ratio (E1), maximum enhanced ratio (Emax), and maximum enhanced time (Tmax), dynamic signal intensity-time curve were obtained during treatment. Residual tumour volumes obtained using DMRI were compared with pathological findings to assess the accuracy of DMRI.
Results
After 1st cycle of NAC, the mean volume of responders decreased insignificantly, P > 0.05, but after NAC, mean volume of residual tumor decreased significantly (P < 0.01). Morphology change: 29 cases showed a concentric shrinkage pattern while 7 cases showed a dendritic shrinkage pattern. Significant differences were found in E1, Emax and Tmax between responders and non-responders (P < 0.05). After 1st cycle of NAC, E1, Emax and Tmax of responders changed significantly (P < 0.001); while there is no significant change in non-responders (P > 0.05). After NAC, dynamic signal intensity-time types were changed in responders, and tended to be significantly flattening, while no significant change was found in non-responders. The residual tumour volume correlation coefficient between DMRI and pathology measurements was very high (r = 0.866, P = 0.000).
Conclusion
DMRI is useful to evaluate the early response to NAC in LABC. The presence and volume of residual disease in LABC patients treated with NAC could be accurately evaluated by DMRI.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Charfare H, Limongelli S, Purushotham AD, et al. Neoadjuvant chemotherapy in breast cancer. Br J Surg, 2005, 92: 14–23.
Wang XH, Geng DY, Gu YJ. The dynamic-contrast MRI manifestation of breast lesions. Radiol Pract (Chinese), 2005, 20: 662–666.
Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR, 2005, 184: 868–877.
Junkermann H, Knopp MV, Schmid H, et al. Verlaufsbeobachtung des Mammakarzinoms unter praoperativer Chemotherapie mit Mammographie, Ultraschall und MR. In: Zentralblatt Radiologie. Berlin: Springer, 1994. 106.
Werner-Wasik M, Xiao Y, Pequignot E, et al. Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys, 2001, 51: 56–61.
Shin KH, Moon SH, Suh JS, et al. Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma. Clin Orthop 2000, 376: 200–208.
Pickles MD, Lowry M, Manton DJ, et al. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat, 2005, 91: 1–10.
Scott AF, Roubidoux MA, Helvie MA, et al. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat, 2005, 92:231–238.
Martincich L, Montemurro F, De Rosa G, et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrastenhanced magnetic resonance imaging. Breast Cancer Res Treat, 2004, 83: 67–76.
George ML, Dzik-Jurasz ASK, Padhani AR, et al. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg, 2001, 88: 1628–1636.
Balu-Maestro C, Chapellier C, Bleuse A, et al. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Res Treat, 2002, 72: 145–152.
Padhani AR. Functional MRI for anticancer therapy assessment. Eur J Cancer, 2002, 38: 2116–2127.
Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed, 2002, 15: 154–163.
Englmeier KH, Hellwig G, Griebel J, et al. Dynamic MR-mammography in virtual reality. Stud Health Technol Inform, 2003, 94: 72–78.
Knopp MV, Junkermann HJ, He B T, et al. MR-Mammographie zum Monitoring von neoadjuvanter Therapie beim Mammakarzinom. Radiologe, 1995, 35(Suppl 1): S81.
Chou CP, Wu MT, Chang HT, et al. Monitoring breast cancer response to neoadjuvant systemic chemotherapy using parametric contrast-enhanced MRI: a pilot study. Acad Radiol, 2007, 14: 561–573.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, X., Peng, W., Tan, H. et al. Evaluation of dynamic contrast-enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Chin. -Ger. J. Clin. Oncol. 9, 637–642 (2010). https://doi.org/10.1007/s10330-010-0706-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10330-010-0706-2